Combined oral contraceptives.

Composition Tri-regol

Ethinyl estradiol + Levonorgestrel.

Manufacturers

Gedeon Richter A.O. (Hungary)

Pharmacological action

Combined hormonal contraceptive for oral administration.

Suppresses ovulation, blocking the release of FSH and LH in the pituitary gland, promotes the secretory transformation of the endometrium.

Increases the viscosity of cervical mucus, which prevents sperm penetration.

Consecutive administration of tablets of the drug containing different amounts of gestagen (levonorgestrel) and estrogen (ethinyl estradiol) allows you to replenish and ensure the concentrations of these hormones in the blood are close to physiological, with subsequent normalization of the menstrual cycle.

When taken orally, the active substances are quickly and completely absorbed from the gastrointestinal tract.

Excreted by the kidneys and intestines.

Side effects of Tri-regol

Dyspepsia, mastalgia, weight gain or loss, decreased glucose tolerance, changes in libido, vaginal bleeding, headaches, mood lability, fatigue, cramps in the calf muscles, skin rashes.

Indications for use

Contraception; Menstrual irregularities.

Contraindications Tri-regol

Pregnancy; - lactation period ( breastfeeding); - serious illnesses liver; - hereditary hyperbilirubinemia (Gilbert syndrome, Dubin-Johnson syndrome, Rotor syndrome); - cholecystitis; - chronic colitis; - severe cardiovascular diseases (including a history); - cerebrovascular diseases (including a history); - thromboembolism and predisposition to them; - liver tumor; - breast or endometrial cancer; - familial forms of hyperlipidemia; - severe arterial hypertension; - heavy diabetes mellitus; - sickle cell anemia; - chronic hemolytic anemia; - bleeding from the vagina of unknown etiology; - migraine; - otosclerosis (aggravated during previous pregnancies); - history of severe idiopathic jaundice during pregnancy; - history of severe skin itching during pregnancy; - history of herpetic infection during pregnancy; - hypersensitivity to the components of the drug.

Directions for use and dosage

For the purpose of contraception:

• internal,
• 1 table each from the 1st-5th day of menstruation,
• preferably before bed.

Start by taking ocher-yellow tablets (6 days), then take apricot-pink tablets (5 days) and then take tablets for 10 days white.

After a week's break (at this time menstrual-like bleeding occurs), the next 21-day course begins.

For medicinal purposes:

• The dosage regimen is determined individually.

Overdose

No information available.

Interaction

The effect is reduced by inducers of microsomal oxidation (rifampicin, barbiturates, phenytoin), broad-spectrum antibiotics (tetracyclines), sulfonamides, pyrazolone derivatives.

Special instructions

The drugs should be used as prescribed by a doctor.

Before starting to use the drug, it is necessary to exclude the presence of pregnancy, conduct a general medical and gynecological examination (measurement of blood pressure, determination of glucose levels in the urine, liver function testing, examination of the mammary glands, cytological smear analysis).

Women over 35 years of age taking hormonal contraceptives are advised to completely stop smoking, because Smoking while taking hormonal contraceptives increases the risk of developing diseases of the cardiovascular system, in particular thrombosis and thromboembolism.

If you are planning a pregnancy, use should be stopped 3 months before its expected onset and a non-hormonal method of contraception should be used.

Instructions

"Tri-Regol" is prescribed for the purpose of oral contraception, as well as for dysmenorrhea and premenstrual syndrome. Take the drug at the same time of day, preferably in the evening. For contraception, take 1 tablet daily for 21 days, starting from the first day. At the end of the course, take a break for a week, during which menstruation should begin. On the 8th day, resume taking Tri-Regola. It is not recommended to stop taking the drug without consulting a doctor.

If you missed another pill, take the drug within the next 12 hours. If more than 36 hours have passed, the degree of contraception is significantly reduced. At this time, you should use additional non-hormonal agents. In this case, you need to continue taking Tri-Regol to avoid bleeding between menstrual periods. After an abortion, the appointment is carried out on the day of the abortion or the next day. The use of Tri-Regol after childbirth is only possible if breastfeeding is excluded. For therapeutic purposes, the drug should be taken only as prescribed by a doctor.

"Tri-Regol" is contraindicated in severe liver diseases (Dubin-Johnson, Gilbert, Rotor syndromes, tumors), cholecystitis, chronic colitis, severe cerebrovascular and cardiovascular diseases, predisposition to thromboembolism, malignant neoplasms (primarily with breast or endometrial cancer), with severe arterial hypertension, familial forms of hyperlipidemia, with endocrine diseases (including severe diabetes mellitus), with chronic hemolytic and sickle cell anemia, vaginal bleeding of unknown origin, migraines, herpes, idiopathic jaundice , during pregnancy and breastfeeding, with hypersensitivity to the components of the product.

"Tri-regol" causes the following side effects: nausea, vomiting, jaundice, swelling of the mammary glands, the appearance of bloody intermenstrual discharge, increased glucose levels, changes in vaginal secretion and libido, headache, decreased emotional background, increased blood pressure, development of venous thromboembolism, thrombosis, changes in body weight, allergic reactions in in the form of rashes and skin itching. Taking the drug should be started after pregnancy has been ruled out, as well as after a series of medical examinations. During the period of using Tri-Regol, you need to undergo gynecological examinations once every six months.

Catad_pgroup Combined oral contraceptives

The most physiological contraceptive that maintains quality sex life. For the treatment of heavy and/or prolonged menstrual bleeding without organic pathology.
INFORMATION PROVIDED STRICTLY
FOR HEALTH PROFESSIONALS

Tri-Regol - official* instructions for use

REGISTRATION NUMBER:

TRADE NAME:

TRI-REGOL®

International nonproprietary name:

ethinyl estradiol + levonorgestrel

DOSAGE FORM:

Film-coated tablets

COMPOUND

Active ingredients:

Tablets I: contain 0.03 mg ethinyl estradiol and 0.05 mg levonorgestrel,
Tablets II: contain 0.04 mg ethinyl estradiol and 0.075 mg levonorgestrel,
Tablets III: Contains 0.03 mg ethinyl estradiol and 0.125 mg levonorgestrel.

Excipients

Tablets I.
Core:
Shell: sucrose, talc, calcium carbonate, titanium dioxide (E171), copovidone, macrogol 6000, colloidal silicon dioxide, povidone, carmellose sodium, red iron oxide (E172).
Tablets II.
Core: colloidal silicon dioxide, magnesium stearate, talc, corn starch, lactose monohydrate (33.0 mg).
Shell: sucrose, talc, calcium carbonate, titanium dioxide (E171), copovidone, macrogol 6000, colloidal silicon dioxide, povidone, carmellose sodium.
Tablets III.
Core: colloidal silicon dioxide, magnesium stearate, talc, corn starch, lactose monohydrate (33.0 mg).
Shell: sucrose, talc, calcium carbonate, titanium dioxide (E171), copovidone, macrogol 6000, colloidal silicon dioxide, povidone, carmellose sodium, yellow iron oxide (E172).

DESCRIPTION

Tablets I
Pink, round, biconvex, film-coated tablets with a glossy surface. White on the break.
Tablets II
White, round, biconvex, film-coated tablets with a glossy surface. White on the break.
Tablets III
Dark yellow, round, biconvex, film-coated tablets with a glossy surface. White on the break.

PHARMACOTHERAPEUTIC GROUP:

combined contraceptive (estrogen + gestagen).

ATX code: G03AB03

PHARMACOLOGICAL PROPERTIES

Pharmacodynamics

Combined (three-phase) oral contraceptive estrogen-progestogen drug. When taken, it inhibits the pituitary secretion of gonadotropic hormones.
Sequential administration of film-coated tablets containing varying amounts of progestogen (levonorgestrel) and estrogen (ethinyl estradiol) provides concentrations of these hormones in the blood close to their concentrations during the normal menstrual cycle and promotes the secretory transformation of the endometrium. The contraceptive effect is associated with several mechanisms. Under the influence of levonorgestrel, the release of releasing factors (luteinizing and follicle-stimulating hormones) of the hypothalamus is blocked, the secretion of gonadotropic hormones by the pituitary gland is inhibited, which leads to inhibition of the maturation and release of an egg ready for fertilization (ovulation).

Ethinyl estradiol maintains the high viscosity of cervical mucus (it makes it difficult for sperm to enter the uterine cavity). Along with the contraceptive effect, the menstrual cycle is normalized by replenishing the level of endogenous hormones with the hormonal components of Tri-Regol® tablets. In seven-day periods, when the next break in taking the drug follows, uterine bleeding occurs.

Pharmacokinetics

Levonorgestrel is rapidly absorbed (less than 4 hours). Levonorgestrel does not have a first-pass effect through the liver. The half-life is 8-30 hours (average 16 hours). Most Levonorgestrel in the blood binds to albumin and sex hormone-binding globulin.

Ethinyl estradiol is rapidly and almost completely absorbed from the gastrointestinal tract. The maximum concentration in plasma is achieved in the range of 1-1.5 hours. The half-life is 26±6.8 hours. Ethinyl estradiol has a “first pass” effect through the liver (the so-called “first pass” effect). Metabolism occurs in the liver and intestines.

When taken orally, ethinyl estradiol is released from the blood plasma within 12 hours.
Ethinyl estradiol metabolites: water-soluble derivatives of sulfate or glucuronide conjugation enter the intestine with bile, where they undergo disintegration with the help of intestinal bacteria. 60% of levonorgestrel is excreted by the kidneys, 40% by the intestines, 40% of ethinyl estradiol is excreted by the kidneys and 60% by the intestines.

INDICATIONS FOR USE

Oral contraception.

CONTRAINDICATIONS

Hypersensitivity to any component of the drug.
Pregnancy, breastfeeding, severe liver diseases, liver tumors, congenital hyperbilirubinemia (Gilbert, Dubin-Johnson and Rotor syndromes), cholelithiasis, cholecystitis, chronic colitis; the presence or indication in the anamnesis of severe cardiovascular (including decompensated heart defects) and cerebrovascular changes, thromboembolism and predisposition to them, phlebitis of the deep veins of the lower extremities, hormone-dependent malignant neoplasms of the genital organs and mammary glands (including suspicion of them), familial forms of hyperlipidemia, arterial hypertension with systolic/diastolic blood pressure 160/100 mm Hg. and above, surgical interventions, surgical operations on the lower extremities, prolonged immobilization, extensive trauma, pancreatitis (including a history), accompanied by severe hypertriglyceridemia and hyperlipidemia, jaundice due to taking medications containing steroids, severe forms of diabetes mellitus, sickle cell anemia, chronic hemolytic anemia, vaginal bleeding of unknown etiology, migraine, hydatidiform mole, otosclerosis with worsening during previous pregnancy(ies); idiopathic jaundice of pregnant women, severe skin itching of pregnant women, history of herpes during pregnancy; smoking over the age of 35, age over 40; lactase deficiency, lactose intolerance, glucose-galactose malabsorption (the dosage form of the drug contains lactose).

WITH CAUTION

Compensated diabetes mellitus without vascular complications, arterial hypertension with systolic/diastolic blood pressure up to 160/100 mm Hg, varicose veins, multiple sclerosis, epilepsy, chorea minor, porphyria, tetany, bronchial asthma, adolescence(without regular ovulatory cycles), uterine fibroids, mastopathy, depression, tuberculosis.

PREGNANCY AND LACTATION

During pregnancy and lactation, taking Tri-Regol® is contraindicated.

METHOD OF APPLICATION AND DOSES

Using the drug for the first time:

Take orally at the same time of the day, if possible in the evening, without chewing and with a small amount of liquid.
For the purpose of contraception in the first cycle, Tri-Regol® is prescribed daily, 1 tablet/day. for 21 days, starting from day 1 of the menstrual cycle, then take a 7-day break, during which typical menstrual bleeding occurs. The next package containing 21 film-coated tablets should be taken on the 8th day after a 7-day break.
The drug is taken as long as there is a need for contraception.
When switching from another oral contraceptive to taking Tri-Regol®, a similar scheme is used.
After an abortion It is recommended to start taking the drug on the same or the next day after surgery.
After childbirth The drug is recommended exclusively for women who are not breastfeeding.
Reception should begin no earlier than the first day of menstruation or cycle.
During lactation, the use of the drug is contraindicated.

If a woman does not take Tri-Regol® within the prescribed period, you should take the missed pill within the next 12 hours. If 36 hours have passed after taking the pill, contraception cannot be considered reliable. However, in order to avoid intermenstrual bleeding, it is necessary to continue taking the drug from the already started package minus the missed tablet(s). At this time, it is recommended to additionally use another, non-hormonal method of contraception (for example, barrier).

SIDE EFFECTS

Side effects observed with the use of the drug are classified into categories depending on the frequency of their occurrence: very often ≥1/10; often >1/100, ≤1/10, sometimes ≥1/1000, ≤1/100; rarely ≥1/10000, ≤1/1000; very rarely ≤1/10000 including isolated reports.
Nausea, vomiting, headache, engorgement of the mammary glands, increased body weight, decreased libido, depressed mood, chloasma, intermenstrual bleeding, in some cases - swelling of the eyelids, conjunctivitis, blurred vision, discomfort when wearing contact lenses (these phenomena are temporary and disappear after discontinuation without prescribing any therapy). Rarely, increased concentrations of triglycerides, blood glucose, decreased glucose tolerance, increased blood pressure, jaundice, hepatitis, liver adenoma, gallbladder diseases (for example, cholelithiasis, cholecystitis), thrombosis and venous thromboembolism, skin rash, hair loss, increased discharge from vaginal candidiasis, increased fatigue, diarrhea. With long-term use, generalized itching, cramps of the calf muscles, hearing loss, increased frequency of epileptic seizures, and deepening of the voice may very rarely occur.

OVERDOSE

Overdose symptoms: nausea, uterine bleeding.
When the first signs of overdose appear in the first 2-3 hours, gastric lavage and symptomatic treatment are recommended. There is no antidote.

INTERACTION WITH OTHER MEDICINES

Use the drug with caution when taking simultaneously:

ampicillin, rifampicin, chloramphenicol, neomycin, polymyxin B, sulfonamides, tetracyclines, dihydroergotamine, tranquilizers, phenylbutazone, since these drugs can weaken the contraceptive effect, it is recommended to additionally use another, non-hormonal contraceptive method;

anticoagulants, coumarin or indanedione derivatives (it may be necessary to urgently determine the prothrombin index and change the dose of the anticoagulant);

tricyclic antidepressants, maprotiline, beta-blockers (bioavailability and therefore toxicity may increase);

oral hypoglycemic drugs, insulin (it may be necessary to change their doses);

bromocriptine (reduced effectiveness);

drugs with possible hepatotoxic effects, primarily dantrolene (risk of increased hepatotoxicity, especially in women over 35 years of age).

SPECIAL INSTRUCTIONS

Before starting to use the drug, it is necessary to exclude pregnancy and conduct a general medical and gynecological examination (breast examination, cytological smear analysis).
While taking the drug, regular gynecological examinations are required every 6 months.
The use of oral contraception is allowed no earlier than 6 months after viral hepatitis and subject to normalization of liver functions.
If there is sharp pain in the upper abdomen, hepatomegaly or signs of intra-abdominal hemorrhage, the presence of a liver tumor may be suspected. In this case, taking the drug should be stopped.
If acyclic bleeding occurs, it is possible to continue taking Tri-Regol® after the attending physician has ruled out organic pathology.
If abnormal liver function is detected during use of the drug, the question of the advisability of continuing to take the drug Tri-Regol® should be decided.
In case of vomiting or diarrhea, the drug should be continued, and it is recommended to additionally use another, non-hormonal method of contraception.
At least 3 months before the planned pregnancy, the drug must be stopped.
Under the influence of oral contraceptives (due to the estrogen component), some laboratory parameters may change (functional parameters of the liver, kidneys, adrenal glands, thyroid gland, blood coagulation and fibrinolytic factors, levels of lipoproteins and transport proteins). The drug should be stopped immediately in the following cases:
- for the first time or worsening migraine-like or unusually severe headache, for acute deterioration of visual acuity, for suspected thrombosis or heart attack;
- with a sharp increase in blood pressure, the appearance of jaundice or hepatitis without jaundice, the occurrence of generalized itching or an increase in epileptic seizures;
- upon pregnancy;
- 6 weeks before the planned operation, with prolonged immobilization (for example, after injury). The effect of the drug on the ability to drive a car and other mechanisms
Taking the drug does not affect the ability to drive a car or operate other mechanisms.

RELEASE FORM

Film-coated tablets.
Tablets I pink - 6 pcs.
Tablets II, white - 5 pcs.
Tablets III dark yellow - 10 pcs.
21 tablets (I, II, III) in an Al/PVC blister. 1 or 3 blisters in a cardboard box with instructions for use.

STORAGE CONDITIONS

List B.
At a temperature of 15-30 °C, out of the reach of children.

Latest update of the description by the manufacturer 15.07.2014

Filterable list

Active ingredient:

ATX

Pharmacological group

Nosological classification (ICD-10)

3D images

Compound

Film-coated tablets
Tablets, I	1 table
active substances:
ethinylestradiol	0.03 mg
levonorgestrel	0.05 mg
excipients
core: colloidal silicon dioxide - 0.275 mg; magnesium stearate - 0.55 mg; talc - 1.1 mg; corn starch - 19.995 mg; lactose monohydrate - 33 mg
shell: sucrose - 22.013 mg; talc - 6.935 mg; calcium carbonate - 2.898 mg; titanium dioxide (E171) - 1.814 mg; copovidone - 0.828 mg; macrogol 6000 - 0.207 mg; colloidal silicon dioxide - 0.123 mg; povidone - 0.074 mg; carmellose sodium - 0.025 mg; iron oxide red (C.I.77491, E172) - 0.083 mg
Tablets, II	1 table
active substances:
ethinylestradiol	0.04 mg
levonorgestrel	0.075 mg
excipients
core: colloidal silicon dioxide - 0.275 mg; magnesium stearate - 0.55 mg; talc - 1.1 mg; corn starch - 19.96 mg; lactose monohydrate - 33 mg
shell: sucrose - 22.013 mg; talc - 6.935 mg; calcium carbonate - 2.898 mg; titanium dioxide (E171) - 1.897 mg; copovidone - 0.828 mg; macrogol 6000 - 0.207 mg; colloidal silicon dioxide - 0.123 mg; povidone - 0.074 mg; carmellose sodium - 0.025 mg
Tablets, III	1 table
active substances:
ethinylestradiol	0.03 mg
levonorgestrel	0.125 mg
excipients
core: colloidal silicon dioxide - 0.275 mg; magnesium stearate - 0.55 mg; talc - 1.1 mg; corn starch - 19.92 mg; lactose monohydrate - 33 mg
shell: sucrose - 22.013 mg; talc - 6.935 mg; calcium carbonate - 2.898 mg; titanium dioxide (E171) - 1.317 mg; copovidone - 0.828 mg; macrogol 6000 - 0.207 mg; colloidal silicon dioxide - 0.123 mg; povidone - 0.074 mg; carmellose sodium - 0.025 mg; iron oxide yellow (C.I.77491, E172) - 0.58 mg

Pharmacological action

Pharmacological action- contraceptive.

Directions for use and doses

Inside, at the same time of day, if possible in the evening, without chewing and with a small amount of liquid.

For the purpose of contraception in the first cycle, Tri-regol ® is prescribed daily, 1 tablet/day for 21 days, starting from the 1st day of the menstrual cycle, then a 7-day break is taken, during which typical menstrual bleeding occurs. Reception from the next package should be started on the 8th day after a 7-day break.

The drug is taken as long as there is a need for contraception.

When switching from another oral contraceptive A similar regimen is used for taking the drug Tri-Regol ®.

Reception should begin no earlier than the 1st day of menstruation or cycle.

Thank you

The site provides reference information for informational purposes only. Diagnosis and treatment of diseases must be carried out under the supervision of a specialist. All drugs have contraindications. Consultation with a specialist is required!

Trade name

Tri-Regol(Tri-regol).

Pharmacological group

Hormonal oral contraceptive.

Release form and composition

The drug Tri-regol is available in three dosage forms: dragees, tablets and film-coated tablets.

One blister contains 21 tablets of three colors: pink - 6 pieces, white - 5 pieces, dark yellow - 10 pieces; packed in a cardboard box. 1 blister of Tri-regol 21 and 7 contains 7 placebo tablets (a substance without medicinal properties) of a reddish-brown color.

1 pink tablet includes ethinyl estradiol 30 mcg and levonorgestrel 50 mcg. Excipients included in the tablet: lactose monohydrate, colloidal silicon dioxide, talc, magnesium stearate and corn starch. Shell components: sucrose, calcium carbonate, talc, copovidone, titanium dioxide (E171), colloidal silicon dioxide, macrogol 6000, povidone, red iron oxide (E172), carmellose sodium. Excipients and coating components are the same for tablets of all colors.

1 white tablet includes levonorgestrel 75 mcg and ethinyl estradiol 40 mcg.

1 dark yellow tablet includes levonorgestrel 125 mcg and ethinyl estradiol 30 mcg.

1 placebo tablet contains iron fumarate - 76.05 mg. Potato starch is added to the excipients.

Description of the drug Tri-regol

The drug Tri-Regol is a round tablet coated in three colors (pink, white and dark yellow). The outer surface of the tablet is glossy, the inside is white.

Placebo tablets are produced with a glossy, round surface, brown at the break.

Pharmacological action of the drug Tri-regol

Pharmacodynamics
Tri-Regol belongs to the group of contraceptive combined (triphasic) estrogen-progestogen drugs. The gestagenic component is represented by levonorgestrel, the estrogenic component is ethinyl estradiol.

Levonorgestrel, by reducing the production of gonadotropic hormones, leads to a decrease in the rate of egg maturation and prevents ovulation. Ethinyl estradiol reduces the possibility of sperm passing into the uterine cavity by increasing the viscosity of cervical mucus.

One of the effects of the drug is normalization of the menstrual cycle, since Tri-regol supplements the level of endogenous hormones due to its components.

Pharmacokinetics
Completely absorbed in the intestine when taken orally. Processed in the liver and intestines, excreted by the kidneys (60% levonorgestrel and 40% ethinyl estradiol) and through the intestines (40% levonorgestrel and 60% ethinyl estradiol).

Indications for use

In gynecological practice, the drug Tri-regol is prescribed for:

• pregnancy prevention (contraception);
• treatment of dysfunctional metrorrhagia;
• treatment of dysmenorrhea of ​​non-organic causes;
• treatment of premenstrual syndrome;
• treatment of menstrual disorders.

Contraindications for use

The use of Tri-Regol is contraindicated in the presence of the diseases listed below:

• pregnancy and lactation;
• the presence of hypersensitivity to any component of the drug in the form of allergic reactions;
• history of severe itching and severe idiopathic jaundice of pregnancy;
• liver diseases (liver tumors, hepatitis, history of Gilbert, Rotor and Dubin-Johnson syndromes, liver failure);
• gallbladder diseases: cholelithiasis, cholecystitis;
• age over 40 years, smoking at the age of 35 years and older;
• severe cardiovascular (severe arterial hypertension, myocarditis, decompensated heart defects, decompensated chronic heart failure) and cerebrovascular (hemorrhagic and ischemic strokes) changes in history, thromboembolism and thrombosis, as well as a predisposition to them;
• vaginal bleeding of unknown etiology;
• severe diabetes mellitus;
• sickle cell and hemolytic anemia;
• disorders of fat metabolism;
• malignant tumors, especially endometrial or breast cancer;
• hydatidiform mole;
• chronic colitis;
• otosclerosis with hearing impairment;
• inflammation of the walls of the deep veins of the lower extremities (phlebitis);
• surgical operations (especially on the legs);
• extensive injuries and prolonged immobilization;
• lactase deficiency (deficiency of the enzyme necessary to digest lactose in milk).

Tri-regol is used with caution in the presence of the following diseases:

• diabetes mellitus in the compensated stage without vascular complications;
• chronic venous insufficiency of the lower extremities;
• arterial hypertension with blood pressure up to 160/100 mm Hg;
• chorea;
• porphyria;
• lack of regular ovulatory cycles during adolescence.

Tri-regol dosage regimen

The drug Tri-Regol is taken orally. The tablets must be swallowed whole with a small amount of water. It is better to take tablets in the evening; the interval between doses should not exceed 36 hours.

For the purpose of contraception, Tri-regol should be taken on the first day of the menstrual cycle. The duration of treatment is 21 days followed by a break of 7 days. During the interval between doses, moderate bleeding is observed, as during menstruation. The tablets are taken in strict order, they are numbered in accordance with the days of the menstrual cycle. The drug should be continued on the 8th day. Tri-regol 21+7 is taken continuously.

If you miss a pill, it must be taken within 12 hours, no later. If there is a break in taking Tri-Regol birth control pills for 36 hours or more, the drug is continued according to the schedule, excluding the missed pill (it is not taken). In this case, pregnancy may occur, therefore, along with taking the drug Tri-regol, you should use other methods of contraception (preferably barrier).

The drug is taken as long as pregnancy prevention is necessary.

For therapeutic purposes, the doctor selects the dose individually in each specific case.

Side effects of the drug Tri-regol

When using Tri-Regol, side effects may include nausea, vomiting, headache, mastalgia (engorgement and tenderness of the mammary glands), mood lability and fatigue, changes in body weight, intermenstrual bleeding, conjunctivitis and temporary visual impairment.

Rare side effects include increased concentrations of glucose and triglycerides in the blood serum, increased blood pressure, changes in the liver (jaundice, hepatitis, liver adenoma), gallbladder diseases (cholecystitis, cholelithiasis), thrombosis and venous thromboembolism, skin rash, hair loss , vaginal candidiasis, diarrhea.

Very rarely, mainly with long-term use of the drug, the occurrence of cramps in the calf muscles, generalized itching, deepening of the voice, an increase in the frequency of epileptic seizures, and hearing loss are noted.

Symptoms of an overdose with Tri-regol

As a result of an overdose of the drug, nausea and uterine bleeding are observed. In this case, you must consult a doctor (to lavage the stomach and prescribe symptomatic therapy.

Interaction of the drug Tri-regol with other drugs
means

Ampicillin, chloramphenicol, rifampicin, polymyxin B, neomycin, sulfonamides, dihydroergotamine, tetracyclines, tranquilizers, phenylbutazones can reduce the contraceptive effect when taken simultaneously with Tri-Regol, disturbing the balance of microflora.

When taken simultaneously, Tri-Regol increases the side effects of hepatotoxic drugs (primarily dantrolene), especially in women over 35 years of age.

When taking the drug Tri-Regol, you may need to adjust the intake of indirect anticoagulants and hypoglycemic drugs, including insulin.

In case of diarrhea or vomiting, absorption of the drug in the intestine is reduced, which leads to a decrease in the contraceptive effect. Taking the drug should be continued, but it is necessary to additionally use a non-hormonal method of contraception.

If moderate bleeding occurs, it is not necessary to stop taking Tri-Regol.

You must immediately stop the course:

• when a migraine-like headache occurs for the first time, or becomes more intense;
• upon pregnancy;
• when there is stabbing pain when coughing or breathing, a feeling of tightness and pain in the chest;
• with acute deterioration of visual acuity;
• with increased frequency of epileptic seizures;
• if thrombosis is suspected;
• if a liver tumor is suspected (aching pain in the right hypochondrium, the appearance of jaundice, enlarged liver);
• with prolonged immobilization after injuries;
• 6 weeks before planned surgery.

Pregnancy and lactation
The use of Tri-Regol is contraindicated during breastfeeding (excreted in small amounts in breast milk) and during pregnancy. Three months before the planned pregnancy, you should stop taking the drug.

Driving vehicles and operating machinery
The drug Tri-Regol does not affect the speed of physical and mental reactions.

Analogues of the drug Tri-regol

• Triquilar is a therapeutic three-phase contraceptive drug. The active ingredients and principle of action are similar to the drug Tri-regol. Manufacturer: Schering, Germany.
• Triziston refers to therapeutic combined estrogen-gestagen drugs. The action and medicinal components are identical to the drug Tri-regol, the dosage of the active ingredients differs. Women with regular heavy loads on the vocal cords (professional lecturers, announcers) should not take the drug. Manufacturer: Schering, Germany.
• Ovidon is a monophasic combined contraceptive drug. Indicated for women with an estrogenic phenotype (feminine appearance), since the drug contains an increased content of levonorgestrel. Manufacturer: Gedeon Richter, Hungary.

Storage conditions and periods

Shelf life – 5 years. After the expiration date, the drug should not be used.
Tri-regol belongs to drugs from list B, which are stored with caution, out of the reach of children and at a temperature of 15 to 30 o C.

Conditions for dispensing the drug Tri-regol in pharmacies

The drug Tri-Regol can be purchased in the pharmacy chain only with a doctor's prescription.

Price of the drug Tri-regol

The average price for the drug Tri-Regol in the Moscow pharmacy chain is:
Tri-regol birth control pills- 163.78 rub.;
Tri-regol film-coated contraceptive pills 21+7 - 460.53 rub.